Orencia Marketing Likely To Focus On Broader Mechanism Of Action
Executive Summary
Bristol-Myers Squibb is setting the stage to differentiate Orencia from other biologic rheumatoid arthritis therapies with a broader mechanism of action claim
You may also be interested in...
Orencia Promos To Focus On Docs, Disease Awareness; No Branded DTC For Now
Professional education efforts will be the centerpiece of Bristol-Myers Squibb's late-February launch of the rheumatoid arthritis treatment Orencia (abatacept) under the company's voluntary direct-to-consumer advertising moratorium for new products
Orencia Promos To Focus On Docs, Disease Awareness; No Branded DTC For Now
Professional education efforts will be the centerpiece of Bristol-Myers Squibb's late-February launch of the rheumatoid arthritis treatment Orencia (abatacept) under the company's voluntary direct-to-consumer advertising moratorium for new products
Bristol Gears Up For Orencia Launch With Creation Of Immunoscience Unit
Bristol-Myers Squibb has created an immunoscience business unit to support the upcoming launch of Orencia (abatacept) for rheumatoid arthritis, U.S. Pharmaceuticals President Anthony Hooper said
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: